2008
DOI: 10.1111/j.1423-0410.2008.01110.x
|View full text |Cite
|
Sign up to set email alerts
|

Blood transfusion requirements and independent predictors of increased transfusion requirements among adult patients on extracorporeal membrane oxygenation – a single centre experience

Abstract: Adult ECMO patients with lower Hb(nadir) require more daily red blood cell and FFP. Hypertension increases daily FFP requirements. Recent antiplatelet agents, larger Hb decline and longer ECMO duration increase daily platelet requirements. Patients with sepsis or on ECMO for medical reasons have longer ECMO duration, which is associated with total transfusion requirements. Some of these factors may be identified early to optimize blood product support.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
71
3

Year Published

2012
2012
2023
2023

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 63 publications
(78 citation statements)
references
References 12 publications
4
71
3
Order By: Relevance
“…ECMO patients often required multiple transfusions [38,39], which may convey an increased risk of transfusion related complications. Previous studies in neonates and animals have demonstrated increases in lipid peroxidation after PRBC transfusions [40][41][42][43].…”
Section: Discussionmentioning
confidence: 99%
“…ECMO patients often required multiple transfusions [38,39], which may convey an increased risk of transfusion related complications. Previous studies in neonates and animals have demonstrated increases in lipid peroxidation after PRBC transfusions [40][41][42][43].…”
Section: Discussionmentioning
confidence: 99%
“…Fresh frozen plasma is widely used to control bleeding disorders, requiring up to 14 plasma units per ECMO day. 9,12 This study evaluates a protocol for the scheduled determination of acquired bleeding disorders and the substitution of blood products as well as coagulation factor concentrates to predefined target values, even in the absence of clinicial bleeding signs. This target-controlled regimen is compared to a coagulation management performed previously, which was based mainly on clinical bleeding signs as a trigger for the administration of blood products.…”
Section: Introductionmentioning
confidence: 99%
“…As the whole system has a biocompatible BIOLINE coating, a pronounced systemic anticoagulation was unnecessary without any thromboembolic complications. This decreased the rate of blood transfusions, which had been considerably higher in previous studies, despite the fact that the current study included patients with multiple trauma and thrombocytopenia 15,16 . The rate of hemorrhagic complications was markedly reduced, which makes its implementation possible in patients with a risk of bleeding, which had been traditionally contraindications for ECMO therapy.…”
Section: Commentmentioning
confidence: 77%